Please login to the form below

Not currently logged in
Email:
Password:

Actelion announces results

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year at CHF 855.2m. The company reported an operating profit of CHF 242.9m compared to CHF 137.2m in H1 2008.

During the six months of 2009, sales of the company's pulmonary arterial hypertension (PAH) drug, Tracleer, reached CHF 739.3m – representing an increase of 23 per cent (in local currencies) compared to the first six months of 2008. The European Commission approved the paediatric dispersible formulation of Tracleer for treatment of PAH in children earlier this month. Sales of Ventavis (also for PAH) increased by 50 per cent in local currencies from CHF 37.9m, in H1 2008 to CHF 61.5m. 

Chief financial officer Andrew Oakley said: "Actelion now expects, unforeseen events excluded, that both total net revenues and cash EBIT [Earnings Before Interest and Tax] - in local currencies - will increase between 16 and 19 per cent for the full year of 2009."

The company reports a pipeline of 10 compounds in clinical development and 25 active projects in drug discovery.

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics